HC Wainwright Issues Positive Forecast for SCTX Earnings

Key Points

• HC Wainwright raised its Q3 2026 EPS forecast for Scribe Therapeutics to a loss of $0.42 per share from its previous estimate of $1.02, while maintaining a Buy rating and a $60 price target.
• Scribe Therapeutics reported a quarterly loss of $3.84 per share, beating the consensus estimate of a $6.20 loss, although revenue of $1.92 million fell short of the $3.10 million expectation.
• Analyst sentiment remains favorable, with four Buy ratings and one Hold rating producing a “Moderate Buy” consensus and an average price target of $51.75; insiders also purchased shares worth approximately $56.3 million during the last quarter.

Scribe Therapeutics Inc. (NASDAQ:SCTX - Free Report) - HC Wainwright upped their Q3 2026 earnings per share (EPS) estimates for shares of Scribe Therapeutics in a report issued on Thursday, September 3rd. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of ($0.42) per share for the quarter, up from their prior estimate of ($1.02). HC Wainwright currently has a "Buy" rating and a $60.00 price objective on the stock. The consensus estimate for Scribe Therapeutics' current full-year earnings is ($3.68) per share. HC Wainwright also issued estimates for Scribe Therapeutics' Q4 2026 earnings at ($0.40) EPS, FY2026 earnings at ($3.68) EPS, Q1 2027 earnings at ($0.47) EPS, Q2 2027 earnings at ($0.55) EPS, Q3 2027 earnings at ($0.68) EPS, Q4 2027 earnings at ($0.82) EPS and FY2027 earnings at ($2.52) EPS.

Scribe Therapeutics (NASDAQ:SCTX - Get Free Report) last issued its quarterly earnings data on Wednesday, September 2nd. The company reported ($3.84) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($6.20) by $2.36. The company had revenue of $1.92 million for the quarter, compared to the consensus estimate of $3.10 million.

A number of other brokerages also recently issued reports on SCTX. Guggenheim assumed coverage on shares of Scribe Therapeutics in a research report on Tuesday, August 18th. They issued a "buy" rating and a $50.00 price target on the stock. Leerink Partners began coverage on shares of Scribe Therapeutics in a research note on Tuesday, August 18th. They set an "outperform" rating and a $37.00 target price for the company. Wells Fargo & Company initiated coverage on shares of Scribe Therapeutics in a report on Tuesday, August 18th. They issued an "overweight" rating and a $60.00 target price on the stock. Zacks Research raised shares of Scribe Therapeutics to a "hold" rating in a research report on Tuesday, September 1st. Finally, Wall Street Zen upgraded Scribe Therapeutics to a "hold" rating in a report on Saturday, August 1st. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $51.75.

Scribe Therapeutics Price Performance

NASDAQ:SCTX opened at $28.67 on Monday. Scribe Therapeutics has a fifty-two week low of $17.31 and a fifty-two week high of $39.60.

Insider Activity at Scribe Therapeutics

In related news, CFO David Parrot bought 2,666 shares of the business's stock in a transaction that occurred on Thursday, July 23rd. The shares were acquired at an average cost of $15.00 per share, with a total value of $39,990.00. Following the completion of the purchase, the chief financial officer directly owned 1,333 shares in the company, valued at $19,995. The trade was a -200.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Behzad Aghazadeh bought 7,905 shares of Scribe Therapeutics stock in a transaction dated Tuesday, July 28th. The stock was purchased at an average price of $18.25 per share, with a total value of $144,266.25. Following the completion of the purchase, the director owned 3,088,888 shares in the company, valued at $56,372,206. This trade represents a 0.26% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders purchased 3,727,237 shares of company stock worth $56,291,746.

Scribe Therapeutics Company Profile

Scribe Therapeutics Inc is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Scribe Therapeutics Inc is based in ALAMEDA, Calif.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source